A Phase 3 interventional study of Apixaban and No systemic anticoagulant prophylaxis in Lymphoma and Acute Lymphoblastic Leukemia, sponsored by Bristol-Myers Squibb. Completed at 96 sites in 12 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2022-03-08.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Lymphoma by Bristol-Myers Squibb — 2 open to participants now, 5 under way, 1 of them phase 3. Lymphoma · Bristol-Myers Squibb.
Among the 42 studies in Lymphoma by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 3, and was the 22nd registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →2 of the 42 studies in Lymphoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, France, Germany
Ages 18+
Turning Point Therapeutics, Inc. · Sites in United States, Australia, Canada and 8 more countries
Ages up to 25
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 17 · Phase 3 5
First in 2006; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 512 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 74 across the 39 interventional studies, 151 across the 3 observational. Of the 36 that completed or were terminated, 17 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Lymphoma by Bristol-Myers Squibb that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06356129Phase 3CelgeneStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | 2027-08-09 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies in Lymphoma by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children aged 1 to \<18 years weighing 6 to \<35 kg randomized to apixaban will receive a fixed dose apixaban based on body weight tier twice a day for approximately 28 days. Children aged 1 to \<18 years weighing ≥ 35 kg will receive 2.5 mg of apixaban twice a day for approximately 28 days. Subjects ≥ 5 years may be administered either 2.5-mg, 0.5-mg tablets or oral solution apixaban. Subjects \< 5years and \< 35 kg may be administered 0.5-mg tablets only
Drug: Apixaban
No systemic anticoagulant prophylaxis
Other: No systemic anticoagulant prophylaxis
The Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-Death
The number of participants with non-fatal deep vein thromboses (DVT) (including asymptomatic and symptomatic), pulmonary embolism (PE), cerebral venous sinus thrombosis (CVST); and venous thromboembolism (VTE) related-death objectively confirmed by a blinded, independent adjudication committee. Symptomatic events are included during the intended treatment period. Asymptomatic events are included from scans up to Day 40.
Time frame: From first dose up to approximately 40 days after first dose
The Number of Participants With Adjudicated Major Bleeding
The number of participants with major bleeding adjudicated by a blinded, independent adjudication committee. Adjudicated major bleeding is defined as bleeding that satisfies one or more of the following criteria: 1. fatal bleeding 2. clinically overt bleeding associated with a decrease in hemoglobin of at least 20g/L (ie, 2g/dL) in a 24-hour period 3. bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS; and/or 4. bleeding that requires surgical intervention in an operating suite, including interventional radiology.
Time frame: From first dose up to approximately 34 days after first dose
The Number of Participants With Non-fatal Asymptomatic Deep Vein Thromboses (DVT)
The number of participants with non-fatal asymptomatic deep vein thromboses (DVT) adjudicated by a blinded, independent adjudication committee
Time frame: From first dose up to approximately 40 days after first dose
The Number of Participants With Non-fatal Symptomatic Deep Vein Thromboses (DVT)
The number of participants with non-fatal symptomatic deep vein thromboses (DVT) adjudicated by a blinded, independent adjudication committee
Time frame: From first dose up to approximately 34 days after first dose
The Number of Participants With Non-fatal Pulmonary Embolism (PE)
The number of participants with non-fatal pulmonary embolism (PE) adjudicated by a blinded, independent adjudication committee
Time frame: From first dose up to approximately 34 days after first dose
The Number of Participants With Cerebral Venous Sinus Thrombosis (CVST)
The number of participants with cerebral venous sinus thrombosis (CVST) adjudicated by a blinded, independent adjudication committee
Time frame: From first dose up to approximately 34 days after first dose
The Number of Participants With Venous Thromboembolism (VTE)-Related-death
The number of participants with venous thromboembolism (VTE)-related-death adjudicated by a blinded, independent adjudication committee
Time frame: From first dose up to approximately 34 days after first dose
The Number of Participants With Major and Clinically Relevant Non-Major Bleeding (CRNMB)
The number of participants with major and clinically relevant non-major bleeding (CRNMB) adjudicated by a blinded, independent adjudication committee CRNM bleeding is defined as bleeding that satisfies one or both of the following: 1. overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition and 2. bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room
Time frame: From first dose up to approximately 34 days after first dose
The Number of Participant Deaths
The number of participant deaths adjudicated by a blinded, independent adjudication committee
Time frame: From first dose date until the end of the treatment period + 30 days (Up to approximately 59 days)
The Number of Participants With an Arterial Thromboembolic Event
The number of participants with an arterial thromboembolic event including paradoxical embolism and stroke adjudicated by a blinded, independent adjudication committee
Time frame: From first dose up to approximately 34 days after first dose
The Number of Participants With a CVAD-Related Infection
The number of participants with a central venous access device (CVAD)-related infection adjudicated by a blinded, independent adjudication committee
Time frame: From first dose up to approximately 34 days after first dose
The Number of Participants Needing Catheter Replacements During the Study
The number of participants needing catheter replacements during the study
Time frame: From first dose up to approximately 34 days after first dose
The Number of Participants With CVAD Patency Restoration Events After Thrombolytic Therapy Use
The number of participants with central venous access device (CVAD) patency restoration events after thrombolytic therapy use
Time frame: From first dose up to approximately 34 days after first dose
The Number Participants Experiencing Superficial Vein Thrombosis Events
The number participants experiencing superficial vein thrombosis events. Clots that occur in a superficial vein ie, cephalic vein, basilic vein (upper extremity) or saphenous vein (lower extremity) confirmed by radiographic imaging.
Time frame: From first dose up to approximately 34 days after first dose
The Number of Participants With Clinically Relevant Non-Major Bleeding Events (CRNMB)
The number of participants with clinically relevant non-major bleeding events (CRNMB) adjudicated by a blinded, independent adjudication committee. CRNM bleeding is defined as bleeding that satisfies one or both of the following: 1. overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition and 2. bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room
Time frame: From first dose up to approximately 34 days after first dose
The Number of Participants With Minor Bleeding Events
The number of participants with minor bleeding events adjudicated by a blinded, independent adjudication committee. Minor bleeding defined as any overt or macroscopic evidence of bleeding that does not fulfill the criteria for either major bleeding or CRNMB
Time frame: From first dose up to approximately 34 days after first dose
The Number of Platelet Transfusions Needed During the Study
The number of platelet transfusions needed during the study. The events are not adjudicated. A subject could have more than one platelet transfusion.
Time frame: From first dose up to approximately 34 days after first dose
Maximum Observed Concentration (Cmax)
The maximum observed concentration (Cmax) was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.
Time frame: pre-dose, 1-4 hours post dose
Trough Observed Concentration (Cmin)
The trough observed concentration (Cmin) was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.
Time frame: pre-dose, 1-4 hours post dose
Area Under the Concentration-Time Curve [AUC(TAU)]
The area under the concentration-time curve \[AUC(TAU)\] was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.
Time frame: pre-dose, 1-4 hours post dose
Anti-FXa Activity
Anti-FXa Activity was measured to characterize the relationship between apixaban plasma concentration and anti-FXa activity in pediatric subjects receiving induction chemotherapy
Time frame: pre-dose and 2.5 hours after dosing on day 7. Day 8 and day 15.
| Milestone | Apixaban | Standard of Care |
|---|---|---|
| Started | 256 | 256 |
| Adverse event analysis population | 250 | 262 |
| Completed | 242 | 249 |
| Not completed | 14 | 7 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Administrative reason by sponsor | 0 | 1 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Participant withdrew consent | 13 | 3 |
The number of participants with non-fatal deep vein thromboses (DVT) (including asymptomatic and symptomatic), pulmonary embolism (PE), cerebral venous sinus thrombosis (CVST); and venous thromboembolism (VTE) related-death objectively confirmed by a blinded, independent adjudication committee. Symptomatic events are included during the intended treatment period. Asymptomatic events are included from scans up to Day 40.
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-Death | 31 | 45 |
The number of participants with major bleeding adjudicated by a blinded, independent adjudication committee. Adjudicated major bleeding is defined as bleeding that satisfies one or more of the following criteria: 1. fatal bleeding 2. clinically overt bleeding associated with a decrease in hemoglobin of at least 20g/L (ie, 2g/dL) in a 24-hour period 3. bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS; and/or 4. bleeding that requires surgical intervention in an operating suite, including interventional radiology.
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With Adjudicated Major Bleeding | 2 | 2 |
The number of participants with non-fatal asymptomatic deep vein thromboses (DVT) adjudicated by a blinded, independent adjudication committee
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With Non-fatal Asymptomatic Deep Vein Thromboses (DVT) | 27 | 38 |
The number of participants with non-fatal symptomatic deep vein thromboses (DVT) adjudicated by a blinded, independent adjudication committee
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With Non-fatal Symptomatic Deep Vein Thromboses (DVT) | 4 | 6 |
The number of participants with non-fatal pulmonary embolism (PE) adjudicated by a blinded, independent adjudication committee
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With Non-fatal Pulmonary Embolism (PE) | 0 | 0 |
The number of participants with cerebral venous sinus thrombosis (CVST) adjudicated by a blinded, independent adjudication committee
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With Cerebral Venous Sinus Thrombosis (CVST) | 0 | 1 |
The number of participants with venous thromboembolism (VTE)-related-death adjudicated by a blinded, independent adjudication committee
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With Venous Thromboembolism (VTE)-Related-death | 0 | 0 |
The number of participants with major and clinically relevant non-major bleeding (CRNMB) adjudicated by a blinded, independent adjudication committee CRNM bleeding is defined as bleeding that satisfies one or both of the following: 1. overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition and 2. bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With Major and Clinically Relevant Non-Major Bleeding (CRNMB) | 13 | 5 |
The number of participant deaths adjudicated by a blinded, independent adjudication committee
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participant Deaths | 1 | 3 |
The number of participants with an arterial thromboembolic event including paradoxical embolism and stroke adjudicated by a blinded, independent adjudication committee
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With an Arterial Thromboembolic Event | 0 | 0 |
The number of participants with a central venous access device (CVAD)-related infection adjudicated by a blinded, independent adjudication committee
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With a CVAD-Related Infection | 1 | 6 |
The number of participants needing catheter replacements during the study
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants Needing Catheter Replacements During the Study | 3 | 2 |
The number of participants with central venous access device (CVAD) patency restoration events after thrombolytic therapy use
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With CVAD Patency Restoration Events After Thrombolytic Therapy Use | 0 | 0 |
The number participants experiencing superficial vein thrombosis events. Clots that occur in a superficial vein ie, cephalic vein, basilic vein (upper extremity) or saphenous vein (lower extremity) confirmed by radiographic imaging.
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number Participants Experiencing Superficial Vein Thrombosis Events | 4 | 2 |
The number of participants with clinically relevant non-major bleeding events (CRNMB) adjudicated by a blinded, independent adjudication committee. CRNM bleeding is defined as bleeding that satisfies one or both of the following: 1. overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition and 2. bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With Clinically Relevant Non-Major Bleeding Events (CRNMB) | 11 | 3 |
The number of participants with minor bleeding events adjudicated by a blinded, independent adjudication committee. Minor bleeding defined as any overt or macroscopic evidence of bleeding that does not fulfill the criteria for either major bleeding or CRNMB
| Participants | Apixaban | Standard of Care |
|---|---|---|
| The Number of Participants With Minor Bleeding Events | 37 | 20 |
The number of platelet transfusions needed during the study. The events are not adjudicated. A subject could have more than one platelet transfusion.
| Platelet Transfusions | Apixaban | Standard of Care |
|---|---|---|
| The Number of Platelet Transfusions Needed During the Study | 266 | 248 |
The maximum observed concentration (Cmax) was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.
| ng/mL | Participants Weight Range ≥ 35 kg | Participants Weight Range 25 to < 35 kg | Participants Weight Range 18 to < 25 kg | Participants Weight Range 10.5 to < 18 kg |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 56.5 ± 36.5 | 63.6 ± 38.6 | 61.4 ± 43.9 | 54.2 ± 46.8 |
The trough observed concentration (Cmin) was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.
| ng/mL | Participants Weight Range ≥ 35 kg | Participants Weight Range 25 to < 35 kg | Participants Weight Range 18 to < 25 kg | Participants Weight Range 10.5 to < 18 kg |
|---|---|---|---|---|
| Trough Observed Concentration (Cmin) | 18.8 ± 57.8 | 18.1 ± 97.4 | 12 ± 142 | 12.9 ± 113 |
The area under the concentration-time curve \[AUC(TAU)\] was measured to assess the pharmacokinetics of oral or enteric apixaban in pediatric subjects receiving induction chemotherapy.
| ng•h/mL | Participants Weight Range ≥ 35 kg | Participants Weight Range 25 to < 35 kg | Participants Weight Range 18 to < 25 kg | Participants Weight Range 10.5 to < 18 kg |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve [AUC(TAU)] | 470 ± 35.3 | 510 ± 42.7 | 453 ± 44.8 | 416 ± 48.5 |
Anti-FXa Activity was measured to characterize the relationship between apixaban plasma concentration and anti-FXa activity in pediatric subjects receiving induction chemotherapy
| Anti-FXa activity (ng/mL) | Participants Weight Range ≥ 35 kg | Participants Weight Range 25 to < 35 kg | Participants Weight Range 18 to < 25 kg | Participants Weight Range 10.5 to < 18 kg |
|---|---|---|---|---|
| Day 7 (Predose) | 55.3 ± 16.4 | 62.2 ± 19.4 | 52.8 ± 16 | 44.2 ± 12.9 |
| Day 7 (2.5 hours) | 78.7 ± 28.8 | 72.1 ± 30.6 | 77.5 ± 30.8 | 87.5 ± 45.5 |
| Day 8 | 55.2 ± 8.96 | — | 47.5 ± 10.6 | 48 ± 11.3 |
| Day 15 | 70.2 ± 28 | 75.3 ± 33.9 | 63.9 ± 21.6 | 64.8 ± 25.3 |
Collected over AEs are collected from the first dose date until the end of the treatment period + 2 days (Up to approximately 31 days) SAEs are collected from the first dose date until the end of the treatment period + 30 days (Up to approximately 59 days). All Cause Mortality was collected from first dose up to DBL date: Sep-13-2021 (up to approximately 6 years.). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixaban | 1/250 (0.4%) | 91/250 (36.4%) | 204/250 (81.6%) |
| Standard of Care | 4/262 (1.5%) | 83/262 (31.7%) | 193/262 (73.7%) |
| Event | Apixaban | Standard of Care |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 15/250 | 16/262 |
| EmbolismVascular disorders | 9/250 | 3/262 |
| PyrexiaGeneral disorders | 7/250 | 7/262 |
| SepsisInfections and infestations | 6/250 | 5/262 |
| Deep vein thrombosisVascular disorders | 2/250 | 6/262 |
| ColitisGastrointestinal disorders | 2/250 | 5/262 |
| ConstipationGastrointestinal disorders | 1/250 | 5/262 |
| HyperglycaemiaMetabolism and nutrition disorders | 4/250 | 2/262 |
| DehydrationMetabolism and nutrition disorders | 1/250 | 4/262 |
| Device related infectionInfections and infestations | 3/250 | 2/262 |
| Event | Apixaban | Standard of Care |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 85/250 | 88/262 |
| ConstipationGastrointestinal disorders | 58/250 | 50/262 |
| Platelet count decreasedInvestigations | 54/250 | 55/262 |
| Alanine aminotransferase increasedInvestigations | 46/250 | 39/262 |
| Abdominal painGastrointestinal disorders | 34/250 | 48/262 |
| HyponatraemiaMetabolism and nutrition disorders | 36/250 | 30/262 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 29/250 | 34/262 |
| Back painMusculoskeletal and connective tissue disorders | 29/250 | 19/262 |
| HyperglycaemiaMetabolism and nutrition disorders | 19/250 | 30/262 |
| ThrombocytopeniaBlood and lymphatic system disorders | 28/250 | 25/262 |
| Age, Continuous(Years) | Apixaban | Standard of Care | Total |
|---|---|---|---|
| Mean | 7.2 ± 4.34 | 7.1 ± 4.39 | 7.2 ± 4.36 |
| Sex: Female, Male(Participants) | Apixaban | Standard of Care | Total |
|---|---|---|---|
| Female | 115 | 107 | 222 |
| Male | 141 | 149 | 290 |
| Ethnicity (NIH/OMB)(Participants) | Apixaban | Standard of Care | Total |
|---|---|---|---|
| Hispanic or Latino | 59 | 63 | 122 |
| Not Hispanic or Latino | 196 | 192 | 388 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Apixaban | Standard of Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 25 | 27 | 52 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 12 | 12 | 24 |
| White | 194 | 194 | 388 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 23 | 22 | 45 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Jul 2021, 68 months.
Results were first posted in Mar 2022, 8 months after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 69. This study's 68 months is above that.
Counting every sponsor, half of 62 studies reached it within 67 months; a quarter within 52 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban